Navigation Links
Nicotine Receptors Could Be Lung Cancer Treatment Target
Date:6/15/2009

Compound inhibited receptors and led to cancer cell death in mouse study

MONDAY, June 15 (HealthDay News) -- In a study of mice with lung cancer, a treatment that targeted nicotine receptors more than doubled the animals' survival time, Italian researchers say.

Nicotine plays a dual role in lung cancer. Changes in genes encoding nicotine receptors not only drive the urge the smoke, but also increase susceptibility to lung cancer. Exposure to nicotine boosts the expression of nicotine receptors, which leads to increased cell proliferation and inhibits the programmed cell death known as apoptosis.

In the new study, published in the June 15 issue of the American Journal of Respiratory and Critical Care Medicine, the compound α-CbT dampened the expression of nicotine receptors and increased apoptosis, prolonging the lives of the mice.

"This research clearly has profound clinical implications regarding the role of nicotine in stimulating lung cancer and nicotine receptor antagonists in treating the disease," said Dr. John Heffner, past president of the American Thoracic Society, in a news release from the society. Heffner, who was not involved in the research, added, "The highly addictive nature of nicotine, however, complicates patients' ability to quit smoking and avoid ongoing nicotine exposure."

Previous research has shown that it's possible to dampen the response of nicotine acetylcholine receptors (nAChRs) using an antagonist called d-tubocurarine/α-Cobratoxin (α-CbT), which specifically targeted the area most linked to increased cell growth.

In the study, researchers grafted human non-small-cell lung carcinoma (NSCLC) onto the lungs of mice and then delayed treatment, allowing the tumors to become well-established.

The mice were then divided into three groups: the untreated group; the standard chemotherapy drug group; and the α-CbT group.

Mice that were categorized as non-obese/severe combined immunodeficient (NOD/SCID) and treated with cisplatin (the standard chemotherapy agent) were found to have a 16 percent longer median survival time than untreated mice. NOD/SCID mice treated with α-CbT had an increased median survival time of 1.7-fold over the cisplatin-treated mice and 2.1-fold over untreated mice.

"The results of this study show that α-CbT, a powerful, high-affinity α-7-nAChR inhibitor, induces antitumor activity against NSCLC by triggering apoptosis," wrote Patrizia Russo of the Lung Cancer Unit of the National Cancer Research Institute in Genoa, Italy, in the news release.

Noncancerous cells did not appear to be affected by α-CbT, suggesting limited toxicity, the researchers found, but they noted that cancer cells with the most receptor binding sites seemed have the greatest treatment sensitivity.

"The goal of this research line is to explore the widest range of possibilities of intervention on the α7-nAChRs," Russo said. "We hope to move further on towards the clinical setting experimentation phase for the assessment of potentially new treatment strategies for NSCLC."

More information

The U.S. National Cancer Institute has more on non-small-cell lung cancer.



-- Jennifer Thomas



SOURCE: American Thoracic Society, news release, June 15, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. AUDIO from Medialink and Commit Lozenge: Wanna Quit Smoking With Therapeutic Nicotine? Just Follow the Directions
2. Nicotine in breast milk disrupts infants sleep patterns
3. Nicotine in Breast Milk Shortens Babys Naptime
4. Initial reaction to nicotine can dictate addiction
5. Rat Study Gets at Root of Nicotine Addiction
6. Nicotine, Chili Peppers Offer Post-Surgery Pain Relief
7. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
8. Genes, brain chemistry may dictate nicotine cravings, says CU-Boulder study
9. Nicotine Plus Alcohol May Be Tough to Beat
10. Nicotine addiction slashed in test of new cigarette smoking strategy
11. Nicotine-Reduced Cigarettes Could Boost Quitting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Nicotine Receptors Could Be Lung Cancer Treatment Target
(Date:12/2/2016)... ... December 02, 2016 , ... The ... Waikiki Beach Resort and Spa in Honolulu, offering local frontline clinicians the opportunity ... management. , The demand for supplemental training related to pain management has ...
(Date:12/2/2016)... ... 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique ... other wearable health technology on the market can deliver all that rejiva can. , ... insights about their health than the usual heart rate and steps taken”, adds Evens ...
(Date:12/2/2016)... ... 02, 2016 , ... Clarify Health Solutions, Inc., the leading ... in an initial round of funding. The round was led by experienced investors ... receive far better care through the application of the best technologies from other ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health radio ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 bioLytical Laboratories, ein Weltführer bei ... den Mitgliedern des Apothekenbundes von Kenia eingeführt. ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... Orthopedic Implants (Including Spinal Implants, Reconstructive Joint Implants, ... Significant Market Share Owing to a Large Global Baby Boomer ... ... According to a new report by Persistence Market Research titled ... Type Segment Projected to Witness a Significantly High CAGR Through ...
(Date:12/2/2016)... , December 2, 2016 On ... trading session in red, while the Dow Jones Industrial Average ... the close of US markets, which prompted Stock-callers this morning ... NuVasive Inc. (NASDAQ: NUVA ), Smith & Nephew ... NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology: